Glaxo Smith Kline Vaccine and anti nausea drug

[RandyW]

Vaccine Trial

The company plans to enroll the first patient in a trial of its lung-cancer vaccine, the largest late-stage study of a treatment for the disease, in September, Slaoui said.

Glaxo is training workers for the start of the trial at 400 centers in 37 countries. The study will follow 2,270 people with early lung cancer for 10 years after they have surgery and receive the shot. Initial results are expected in 2012.

A mid-stage study presented by the company at a conference in Chicago this month showed the vaccine reduced the relapse risk by 27 percent in 182 patients with early non-small cell lung cancer after surgery, compared to 16 percent in studies of thousands of patients treated with chemotherapy.

Glaxo executives also disclosed late-stage data that showed the anti-nausea drug Rezonic worked better when combined with Zofran, another anti-nausea drug the company makes and which lost patent protection last year. The company plans to seek permission to sell Rezonic in the first half of 2008.